Supplementary Table S1: Most frequent ocular and nonocular adverse events (at least 2% in any group) by preferred term (safety set)

Primary system organ class Preferred term, n (%)	T&E ranibizumab 0.5 mg+laser n=126	T&E ranibizumab 0.5 mg n=126	PRN ranibizumab 0.5 mg n=118
Any ocular AE, Total	58 (46.0)	63 (50.0)	46 (39.0)
Cataract*†	5 (4.0)	7 (5.6)	7 (5.9)
Conjunctival haemorrhage*	5 (4.0)	11 (8.7)	6 (5.1)
Dry eye	6 (4.8)	3 (2.4)	4 (3.4)
Vitreous floaters†	0 (0.0)	1 (0.8)	4 (3.4)
Eye pain*	8 (6.3)	7 (5.6)	3 (2.5)
Ocular hypertension*†	7 (5.6)	2 (1.6)	3 (2.5)
Eye irritation	2 (1.6)	4 (3.2)	2 (1.7)
Macular oedema	2 (1.6)	3 (2.4)	2 (1.7)
Diabetic retinal oedema	4 (3.2)	2 (1.6)	1 (0.8)
Glaucoma*†	3 (2.4)	1 (0.8)	1 (0.8)
Conjunctivitis	6 (4.8)	2 (1.6)	0 (0.0)
Keratitis	1 (0.8)	3 (2.4)	0 (0.0)
Lacrimation increased*	1 (0.8)	4 (3.2)	0 (0.0)
Macular fibrosis	3 (2.4)	0 (0.0)	0 (0.0)
Retinal haemorrhage*	2 (1.6)	3 (2.4)	0 (0.0)
Vitreous haemorrhage*†	8 (6.3)	2 (1.6)	0 (0.0)
IOP increased*†	2 (1.6)	7 (5.6)	5 (4.2)
Any nonocular AE, Total	97 (77.0)	99 (78.6)	83 (70.3)
Blood and lymphatic system disorders	5 (4.0)	6 (4.8)	7 (5.9)
Anaemia	4 (3.2)	5 (4.0)	5 (4.2)
Gastrointestinal disorders	22 (17.5)	18 (14.3)	13 (11.0)
Diarrhoea	4 (3.2)	4 (3.2)	7 (5.9)
General disorders and administrative site conditions	14 (11.1)	13 (10.3)	14 (11.9)
Oedema peripheral	7 (5.6)	5 (4.0)	3 (2.5)
Infections and infestations	56 (44.4)	54 (42.9)	42 (35.6)
Influenza	9 (7.1)	10 (7.9)	8 (6.8)
Nasopharyngitis	11 (8.7)	10 (7.9)	8 (6.8)
Cystitis	2 (1.6)	2 (1.6)	6 (5.1)
Bronchitis	11 (8.7)	1 (0.8)	5 (4.2)
Urinary tract infection	9 (7.1)	11 (8.7)	5 (4.2)
Investigations	11 (8.7)	21 (16.7)	14 (11.9)
Blood urine present	2 (1.6)	3 (2.4)	5 (4.2)
Musculoskeletal and connective tissue disorders	21 (16.7)	23 (18.3)	13 (11.0)
Back pain	8 (6.3)	10 (7.9)	3 (2.5)
Vascular disorders	28 (22.2)	23 (18.3)	18 (15.3)
Hypertension	20 (15.9)	18 (14.3)	8 (6.8)

Safety set consisted of all patients who received at least one active application of study treatment and had at least one postbaseline safety assessment

*suspected to be related to ocular injection

†suspected to be related to treatment

A patient with multiple occurrences of a preferred term is counted only once in the preferred term row

A patient with multiple adverse events within a primary system organ class is counted only once in the total row

Percentages are based on the number of patients in the safety set in the specific treatment group

AE, adverse event; IOP, intraocular pressure; PRN, pro re nata; T&E, treat-and-extend